| Zacks Company Profile for Neurocrine Biosciences, Inc. (NBIX : NSDQ) |
|
|
| |
| • Company Description |
| Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
Number of Employees: 1,800 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $134.92 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 788,625 shares |
| Shares Outstanding: 98.97 (millions) |
| Market Capitalization: $13,352.47 (millions) |
| Beta: 0.24 |
| 52 Week High: $157.98 |
| 52 Week Low: $84.23 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
7.93% |
3.89% |
| 12 Week |
33.08% |
11.94% |
| Year To Date |
-1.16% |
-7.43% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Kyle W. Gano - Chief Executive Officer and Director
William H. Rastetter - Chairman of the Board of Directors
Matthew C. Abernethy - Chief Financial Officer
Kevin C. Gorman - Director
Gary A. Lyons - Director
|
|
Peer Information
Neurocrine Biosciences, Inc. (GSAC)
Neurocrine Biosciences, Inc. (CASI)
Neurocrine Biosciences, Inc. (ALCD.)
Neurocrine Biosciences, Inc. (OMNN)
Neurocrine Biosciences, Inc. (CGPI.)
Neurocrine Biosciences, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 64125C109
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
|
|
Share - Related Items
Shares Outstanding: 98.97
Most Recent Split Date: (:1)
Beta: 0.24
Market Capitalization: $13,352.47 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $1.31 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $3.79 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 12.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 25.75% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/30/25 |
|
|
|
| |
